Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG-Reference-Cited by-同舟云学术

Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG

Published:2017-12-29 Issue:4 Volume:97 Page:573-584
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Scappaticci Gianni B.,Marini Bernard L.,Nachar Victoria R.,Uebel James R.,Vulaj Vera,Crouch Ashley,Bixby Dale L.,Talpaz Moshe,Perissinotti Anthony J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3217-1/fulltext.html

Reference34 articles.

1. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M, National Comprehensive Cancer N (2016) Acute myeloid leukemia, version 2.2016. J Natl Compr Cancer Netw 11(9):1047–1055

2. Visser O, Trama A, Maynadie M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC, Group RW (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 48(17):3257–3266. https://doi.org/10.1016/j.ejca.2012.05.024

3. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk KM, Verdonck LF, Beck J, Dohner H, Gratwohl A, Pabst T, Verhoef G, Dutch-Belgian Cooperative Trial Group for H-O, German AMLSG, Swiss Group for Clinical Cancer Research Collaborative G (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361(13):1235–1248. https://doi.org/10.1056/NEJMoa0901409

4. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249–1259. https://doi.org/10.1056/NEJMoa0904544

5. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD (2006) Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108(1):63–73. https://doi.org/10.1182/blood-2005-11-4354

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?;The Oncologist;2022-05-12

2. Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia;Hemato;2021-08-18

3. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2021-06

4. Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review;PLOS ONE;2021-03-30

5. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults;Blood Advances;2020-08-06